Paloma Partners’s BridgeBio Pharma BBIO Stock Holding History

Paloma Partners’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-6,437	Closed	-$242K	–	1656
2020 Q3	$242K	Buy	+6,437	New	+$203K	0.01%	1630

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

SUT

SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Paloma Partners's BBIO Position: Q4 2020 in Review

Paloma Partners sold out of BridgeBio Pharma (BBIO) in Q4 2020, closing a stake of 6,437 shares — an estimated $242K sold.

Paloma Partners first reported a position in BBIO in Q3 2020 and held it in 1 quarter. The position peaked at $242K in Q3 2020. 161 funds tracked by Wall St. Rank hold BBIO as of Q4 2020.

Paloma Partners reported no remaining BridgeBio Pharma position as of Q4 2020 after selling out during the quarter.
Paloma Partners sold 6,437 BridgeBio Pharma shares in Q4 2020, an estimated $242K.
Paloma Partners first reported a position in BridgeBio Pharma in Q3 2020 and held it in 1 quarter.
Paloma Partners's BridgeBio Pharma position peaked at $242K in Q3 2020.
161 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2020.

Based on Paloma Partners's 13F filing for Q4 2020, filed 16 Feb 2021.